Stock AnalizAltria Group, Inc. MO
Medicinal Chemicals and Botanical Products · data as of November 13, 2026
Altria Group, Inc. (MO) is a healthcare company listed in the US with a market value of about $130.8B. In the twelve months to September 30, 2026 it had revenue of $23.5B and net income of $8.1B, a net margin of 34.5%.
Its overall Stock Analiz score is 2.8 out of 5 (average). The strongest part is value (4/5); the weakest is future growth (0/5).
Key numbers: a P/E of 16.2, a price to free cash flow of 14.4, 5-year revenue growth of -2% a year, a 5-year average ROIC of 36%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 35% below the current price.
Score: 2.8 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- PEG below 1.5
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
- Profitable 5 years in a row
- Positive free cash flow
Checks not passed
- Price below intrinsic value (DCF, moderate assumptions)
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- ROE above 15%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $23.5B | $23.3B | $24.0B | $24.5B | $25.1B | $26.0B | $26.2B | $25.1B | $25.4B | $25.6B | $25.7B |
| Net income | $8.1B | $6.9B | $11.3B | $8.1B | $5.8B | $2.5B | $4.5B | -$1.3B | $7.0B | $10.2B | $14.2B |
| Free cash flow | $9.1B | $9.1B | $8.6B | $9.1B | $8.1B | $8.2B | $8.2B | $7.6B | $8.2B | $4.7B | $3.6B |
| EPS (diluted) | $4.85 | $4.12 | $6.54 | $4.57 | $3.19 | $1.34 | $2.40 | $-0.70 | $3.68 | $5.31 | $7.28 |
| Net margin | 34.5% | 29.8% | 46.9% | 33.2% | 23.0% | 9.5% | 17.1% | -5.1% | 27.5% | 40.0% | 55.3% |
| ROIC | — | 33.0% | 40.9% | 37.9% | 40.9% | 28.3% | 21.8% | 23.8% | 24.4% | 25.9% | 21.4% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 11 analysts is $73.45, 7% below the current price; targets range from $59.00 to $85.00; the consensus rating is “Hold”; expected EPS is $5.69 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Altria Group’s P/E ratio?
About 16.2, based on the last twelve months of diluted earnings per share (forward P/E about 13.8).
Is Altria Group stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 35% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Altria Group pay a dividend?
Yes. The dividend yield is about 5.74%, and it has paid dividends for 10 years in our data.
Is Altria Group a good stock to buy?
We do not give buy or sell advice. Altria Group scores 2.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.